MDGL Madrigal Pharmaceuticals, Inc.

NASDAQ
$507.56

Madrigal Pharmaceuticals, Inc. (MDGL) is expected to report earnings on October 29, 2026, before the market open. The consensus earnings estimate is a loss of $1.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.4% since its last earnings release on July 30, 2026.

Madrigal Pharmaceuticals Beat Consensus Estimates
Thursday, July 30, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($1.00)
Rev est $392.53M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $500.60

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow